IL13 and Alzheimer disease: Oral administration of EGCG (50 mg/kg) to APP/PS1 transgenic AD model mice for 4 months was found to significantly alleviate cognitive deficits in mice, improve dendritic integrity and synaptic protein expression levels in the brain, significantly reduce Aβ plaques in the hippocampus of mice, and alleviate the neuroinflammatory response by reducing microglial activation, inhibiting the secretion of pro-inflammatory cytokines IL-1β, and increasing the secretion of anti-inflammatory cytokines interleukin-10 (IL-10) and interleukin-13 (IL-13) [189].